Ivosidenib: all 55 studies that test it
Page 1 of 1. Open to participants first (25), then studies with results posted, then the rest; newest registration first within each.
- Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract CancerNot yet recruitingNCT07745296Phase 3
- Ivosidenib as Maintenance Therapy in Transplant-Ineligible IDH1-mutated AML and HR-MDSRecruitingNCT07607418Phase 2
- Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML PatientsRecruitingNCT07507760Phase 2
- Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leukemia (AML) and IDH1 Mutation, in Complete Remission After Intensive Chemotherapy.Not yet recruitingNCT07463768Phase 2
- A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid LeukemiaRecruitingNCT07392242Phase 2
- Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 CholangiocarcinomaRecruitingNCT07260175Phase 2
- MRD-positive AML Clinical StudyRecruitingNCT07131059Not applicable
- A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal ImpairmentRecruitingNCT07006688Phase 1
- Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) MutationRecruitingNCT06717958Phase 2
- Ivosidenib as Post-HSCT Maintenance for AMLRecruitingNCT06707493Phase 2
- Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AMLRecruitingNCT06611839Phase 1/2
- Lvosidenib (AK112) Combined With CapeOX and Radiotherapy in Patients With Unresectable Metastatic MSS-type Colorectal CancerNot yet recruitingNCT06593548Phase 2
- Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 MutationRecruitingNCT06465953Phase 3
- Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene MutationRecruitingNCT06291987Phase 1
- Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid LeukemiaRecruitingNCT06265545Not applicable
- Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment RegimenRecruitingNCT06127407Phase 3
- An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.RecruitingNCT05907057Phase 3
- Personalized Medicine for Advanced Biliary Cancer PatientsRecruitingNCT05615818Phase 3
- IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)RecruitingNCT05401097Phase 2
- Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in RemissionRecruitingNCT05010772Phase 1
- Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaRecruitingNCT04774393Phase 1/2
- CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeRecruitingNCT04493164Phase 2
- Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic MalignanciesRecruitingNCT03471260Phase 1/2
- Study of Biomarker-Based Treatment of Acute Myeloid LeukemiaRecruitingNCT03013998Phase 2/3
- Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 MutationRecruitingNCT02074839Phase 1
- A Phase 2 Study of Ivosidenib in Previously Treated Japanese Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 MutationActive, not recruitingNCT06081829Phase 2Results posted
- Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant CholangiocarcinomaTerminatedNCT05921760Phase 1/2Results posted
- Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)Active, not recruitingNCT04195555Phase 2Results posted
- Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic CholangiocarcinomaTerminatedNCT04088188Phase 1Results posted
- Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant TumorsCompletedNCT04056910Phase 2Results posted
- A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary SiteCompletedNCT03498521Phase 2Results posted
- Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 MutationActive, not recruitingNCT03173248Phase 3Results posted
- Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)Active, not recruitingNCT03155620Phase 2Results posted
- Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy)CompletedNCT02989857Phase 3Results posted
- A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction ChemotherapyActive, not recruitingNCT02677922Phase 1/2Results posted
- Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 MutationActive, not recruitingNCT06501625Phase 1/2
- An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic CholangiocarcinomaActive, not recruitingNCT05876754Phase 3
- A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)Active, not recruitingNCT05756777Phase 1
- Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic AdenocarcinomaActive, not recruitingNCT05209074Phase 1
- Ivosidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH1Active, not recruitingNCT05030441Phase 2
- AG-120 in People With IDH1 Mutant ChondrosarcomaActive, not recruitingNCT04278781Phase 2
- Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT04250051Phase 1
- A China Bridging Study of Ivosidenib in r/r AML Subjects With an IDH1 MutationCompletedNCT04176393Phase 1
- A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDSWithdrawnNCT04044209Phase 2
- A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive ChemotherapyActive, not recruitingNCT03839771Phase 3
- IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell TransplantationCompletedNCT03564821Phase 1
- IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic SyndromeActive, not recruitingNCT03503409Phase 2
- Study of AG-120 and AG-881 in Subjects With Low Grade GliomaCompletedNCT03343197Phase 1
- A Study of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic FunctionCompletedNCT03282513Phase 1
- Japanese Bridging Study of Ivosidenib (AG-120) in Healthy SubjectsCompletedNCT03071770Phase 1
- Drug-Drug Interaction Study of AG120 in Healthy SubjectsCompletedNCT02831972Phase 1
- Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 MutationActive, not recruitingNCT02632708Phase 1
- Food Effect Study of AG120 in Healthy SubjectsCompletedNCT02579707Phase 1
- Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-AG-120CompletedNCT02489513Phase 1
- Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 MutationCompletedNCT02073994Phase 1